1-(3,4-二羟基苯基)-2-(异丙基氨基)-1-丙酮 | 28227-96-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3,4-二羟基苯基)-2-(异丙基氨基)-1-丙酮
• 中文别名: 3',4'-二羟基-alpha-(异丙基氨基)苯丙酮
• 英文名称: Phenisonone
• 英文别名: 1-(3,4-dihydroxyphenyl)-2-(propan-2-ylamino)propan-1-one
• CAS: 28227-96-5；715646-49-4
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.27
• InChiKey: GPHUDPVNXDFRCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
  申请人：Astion Development A/S

  公开号：EP1719507A1

  公开（公告）日：2006-11-08

  The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.

  本发明提供了治疗皮肤结缔组织疾病，特别是治疗红斑狼疮皮肤病的有效而安全的药物。这些药物包括作为治疗活性成分的β2肾上腺素受体激动剂。此外，本发明还涉及不具有皮肤过敏特性的皮肤病治疗组合物，该组合物含有对映体纯的或β2肾上腺素受体激动剂的富集R-对映体。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Treatment of connective tissue diseases of the skin
  申请人：Weidner Sloth Morten

  公开号：US20060235048A1

  公开（公告）日：2006-10-19

  The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta 2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta 2 adrenoceptor agonist.

  本发明提供了治疗皮肤结缔组织疾病，特别是治疗红斑狼疮皮肤病的有效而安全的药物。这些药物包括作为治疗活性成分的 beta 2 肾上腺素受体激动剂。此外，本发明还涉及不具有皮肤过敏特性的皮肤病治疗组合物，该组合物含有对映体纯度高或富含 R-对映体的 β2-肾上腺素受体激动剂。 2 肾上腺素受体激动剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13